Serum Fibroblast Growth Factor 19 and Total Bile Acid Concentrations Are Potential Biomarkers of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus

Autor: Xiaoqing Ni, Yunjuan Gu, Shiwei Cui, Xinlei Wang, Jin Yuan, Hui Zhao, Yezi Sun, Hua Huang, Rongping Zhang, Rong OuYang, Yi Sun, Jianyou Su, Minxia Zhu, Renan Chang, Wei Chen, Jie Yuan
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Adult
Male
medicine.medical_specialty
Carcinoma
Hepatocellular
Article Subject
endocrine system diseases
Adolescent
medicine.drug_class
Fibroblast growth factor
Gastroenterology
General Biochemistry
Genetics and Molecular Biology
Bile Acids and Salts
03 medical and health sciences
0302 clinical medicine
Internal medicine
Diabetes mellitus
Carcinoma
medicine
Biomarkers
Tumor
Humans
In patient
Aged
General Immunology and Microbiology
Bile acid
business.industry
Liver Neoplasms
nutritional and metabolic diseases
Type 2 Diabetes Mellitus
FGF19
General Medicine
Middle Aged
medicine.disease
digestive system diseases
Neoplasm Proteins
Fibroblast Growth Factors
030104 developmental biology
Diabetes Mellitus
Type 2
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Medicine
Female
business
Research Article
Zdroj: BioMed Research International
BioMed Research International, Vol 2020 (2020)
ISSN: 2314-6141
2314-6133
Popis: Purpose. Type 2 diabetes mellitus (T2DM) carries a high risk of hepatocellular carcinoma (HCC). Both serum fibroblast growth factor 19 (FGF19) and bile acid concentrations are associated with T2DM and HCC. We aimed at evaluating the relationships between FGF19 and bile acid concentrations and HCC in patients with T2DM. Methods. Twenty-seven healthy volunteers (control group), 27 patients with T2DM (T2DM group), 16 patients with newly diagnosed HCC (HCC group), and 10 T2DM patients with newly diagnosed HCC (T2DM-HCC group) were studied at the Affiliated Hospital of Nantong University between June 2016 and June 2017. The serum concentrations of serum FGF19 and total bile acids (TBA) were measured in all the participants. Correlation analysis and multiple stepwise regression analysis of the FGF19 and TBA concentrations were performed in all the participants and in the four groups. Results. The concentrations of FGF19 were 220.5 pg/ml, 185.1 pg/ml, 115.8 pg/ml, and 70.4 pg/ml in the HCC, T2DM-HCC, control, and T2DM groups, respectively (p<0.001), and the TBA concentrations were 21.75 μmol/l, 14.25 μmol/l, 3.6 μmol/l, and 3.1 μmol/l (p<0.001). There were positive correlations between the FGF19 and TBA concentrations across all the participants (r = 0.777; p<0.001), and in the control (r = 0.400; p=0.039), T2DM (r = 0.477; p=0.012), HCC (r = 0.684; p=0.003), and T2DM-HCC (r = 0.673; p=0.033) groups. Conclusions. Simultaneous increase of serum FGF19 and TBA levels may be used as indicators of HCC screening at early stage in patients with T2DM.
Databáze: OpenAIRE
Externí odkaz: